On Tuesday, 8 March, I had the privilege of joining the Asia Pacific Johnson & Johnson International Women’s Day virtual event in a thought-provoking discussion with my colleagues Ellie Xie and Tim Schmid on the prevalence and challenges presented by unconscious bias.
This is a crucial conversation for leaders to have if we are to heed the call to #BreaktheBias – the theme for this year’s #IWD.
It is not until we engage in tough conversations and reflect on our own beliefs and behaviour that we begin to challenge and ask ourselves: are we are doing everything we can to foster a work environment that celebrates diversity and support women in their career?
Breaking the Bias and achieving real change is driven through collaborative effort and allyship. This is a key reason why I accept and embrace the responsibility to drive accountability, champion robust talent practices and transform how we drive DE&I to achieve our 2025 Health for Humanity goals.
Research shows that companies with a diverse culture outperform those that don’t, and in fact, creating diverse teams is rewarding – leaders have to accept that team members will often challenge their thinking. This is an area where we have made some progress at #JnJ.
I want to thank my colleague Nadia Yu for moderating a fantastic discussion that saw each of us commit to actions to help #BreakTheBias in 2022. For my part, I will continue to champion the voice of women in the Asia Pacific region, and work to ensure they have the equitable opportunities for a greater career at J&J and also many opportunities whether that be globally or in other regions.
Embracing these uncomfortable conversations is the most important and constructive action I can take to further advance our legacy of 130-years of supporting women to succeed.
#IWD2022 #BreakTheBias #MyCompany
-
![No alternative text description for this image]()
This Lung Cancer Awareness Month we should collectively celebrate the significant treatment advances made possible through #innovative #pharmaceutical #research.
We should also acknowledge the significant and sustained investment required to develop medicines that can outsmart cancer, especially a form as deadly as #lungcancer.
Please take a moment to read and comment on my thoughts about the need for greater recognition of the many years of investment and ingenuity that underpin medical breakthroughs in the fight against #cancer.
#LungCancerAwarenessMonth
![It takes years of investment and ingenuity to add years to the lives of people with cancer]()
Chris Hourigan on LinkedIn
There are things in life we should never take for granted.
This #WorldSightDay my thoughts are with the children and adults affected by Inherited Retinal Diseases, a broad group of genetic conditions that can cause blindness.
Fortunately, recent advances in gene therapy and stem cell technology provide hope that it may soon be possible to save the sight of people with these forms of retinal disease.
As we work towards a new treatment era, it is important to raise awareness of the significant physical, emotional and mental health impact of vision loss.
It is also timely to reflect on the value of transformative medicines to our society and the importance of renewed focus on eye health within national health agendas.
You can read my thoughts in this article.
#WSD2021 #LoveYourEyes
![How much do we value sight?]()
Chris Hourigan on LinkedIn
This week I had the opportunity to share regional and global perspectives on health policy and investment with industry colleagues, patient advocates and government advisers in Australia during a discussion with publisher Paul Cross at the #BioPharmaDispatch Conference.
Falling just a week after the Federal Budget, the conversation quickly turned to pharmaceutical investment, learnings from the #COVID19 pandemic, and what the future of medical innovation and access looks like in reimbursed markets like Australia.
Please take a moment to read a summary of the thoughts I shared at the conference.
#mycompany #Janssen #pharmaceutical #dobetter
![Time for long-term, strategic outlook on healthcare]()
Chris Hourigan on LinkedIn
Today, on #InternationalClinicalTrialsDay, I’m proud to share that more than ever, Asia Pacific holds a prominent place in the design and delivery of clinical trials and medical research at The Janssen Pharmaceutical Companies of Johnson & Johnson.
I consider that a critical part of my role as Company Group Chairman of Janssen in Asia Pacific is to work closely with Zili Li, our regional head of R&D, to advance an ‘Asia-Led’ outlook and approach to clinical research that addresses unmet medical needs in our region.
At the same time, government support is required to create environments conducive to clinical trials and access to medicines. Please take a few moments to read my thoughts in this article.
#mycompany #research #clinicaltrials
![An ‘Asia-Led’ Outlook for Clinical Trials]()
Chris Hourigan on LinkedIn
Today in Asia Pacific, we woke to exciting news of the release of Phase 3 ENSEMBLE trial interim data. This is a highly significant moment on our road to a vaccine and Johnson & Johnson's response to COVID-19. Top-line data indicate that a single dose of the #Janssen COVID-19 vaccine candidate is 66% effective at preventing moderate-to-severe COVID-19, just 28 days after vaccination. Importantly, the Janssen COVID-19 vaccine candidate was 85% effective in preventing severe COVID-19 disease and demonstrated complete protection against COVID-19-related hospitalisation and death, 28 days following vaccination.
For our region, it is very encouraging to know that our vaccine candidate is compatible with standard vaccine distribution channels, which makes it easier to get it to the people who need it. We look forward to working with governments and partners to secure equitable access across Asia Pacific.
I share the optimism of Alex Gorsky for the road ahead and like him, hope this news serves as a reminder of the power of science in changing the trajectory of health for humanity.
#sciencewillwin #mycompany
Today Johnson & Johnson announced positive topline Phase 3 clinical trial results for our single-dose COVID-19 vaccine candidate. I sent the following message to our company’s 135,000 employees, and wanted to share it with the wider community. I hope this news serves as a welcome reminder of the transformative power of science—and the possibility of a better, healthier future. #COVID19
It is a great honour for Johnson & Johnson to receive a top three ranking once again in this year’s Access to Medicine Foundation Index. It is a hard-earned accolade made possible by a deeply entrenched commitment to the pursuit of equitable access in every facet of our global business. If you have a moment, read my thoughts on access challenges and opportunities in Asia Pacific and our efforts in this area.
#mycompany
![Podium place in global Access to Medicine Foundation Index]()
Chris Hourigan on LinkedIn
What do parents need to know about protecting their children’s mental and physical health while returning to school during the COVID-19 pandemic?
ワクチンへの道シーズン２エピソード７
米国での学校再開による安全性の課題
パンデミックの中、学校に戻る子どもたちの心と体の健康を守るために親御さんが知っておくべきこととは？司会者リサ・リン氏が専門家とともに掘り下げます。
フルバージョンはこちら
https://lnkd.in/gUMcUyG
米国ジョンソン・エンド・ジョンソンが制作する「ワクチンへの道」シーズン２では、新型コロナウイルスのパンデミックを収束させるための医学やワクチンについて、科学者、グローバルヘルスリーダーや専門家などをインタビューします。
It is with excitement and energy that I step into my new role as Company Group Chairman for #Janssen Asia Pacific. With responsibility for 8 markets across the most dynamic & populous region globally, I feel humbled to be working with a team committed to supporting patients as our #1 priority.
Firstly, I want to thank my colleagues and the Management Committee of Janssen Japan for making the past 5 years such a career highlight. The results we delivered would not have been possible without an appetite for innovation and dedication to new ways of working. Arigato gozaimasu!
I also acknowledge the support and dedication of my colleagues from the Asia Pacific Leadership Team – especially Ai Hua Ong, who will now lead and elevate Government Affairs & Policy for Johnson & Johnson in Asia Pacific. I thank Ai Hua and wish her great success!
Since joining #JNJ in 2005, I’ve worked across 5 countries – each with unique challenges & opportunities. The next chapter offers endless prospects during a critical time of growth for our industry and region.
Working in sync with global leaders, I am confident that the team I lead in Asia Pacific will set new standards in maximising access to innovative medicines, addressing unmet medical needs and cementing trust with key stakeholders.
-
![No alternative text description for this image]()
Dr. Phillips shares how the COVID-19 pandemic can uniquely impact kids’ mental health, and the important symptoms parents should look out for in this clip from ”The Road to a Vaccine.”
ワクチンへの道シーズン2 エピソード4
この８ヶ月で私たちが学んだこととは。
このパンデミックが子供たちにどのように精神的な影響を与えるか、そして親御さんが注意すべき重要な症状についてジョンソン・エンド・ジョンソン最高医療責任者のジャクリーン・フィリップス博士がお話しします。
フルバージョンはこちら
https://lnkd.in/gUMcUyG
米国ジョンソン・エンド・ジョンソンが制作する「ワクチンへの道」シーズン２では、新型コロナウイルスのパンデミックを収束させるための医学やワクチンについて、科学者、グローバルヘルスリーダーや専門家などをインタビューします。
